Skip to main content

Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.

Publication ,  Journal Article
Huang, L; Yuen, TT-T; Ye, Z; Liu, S; Zhang, G; Chu, H; Yue, J
Published in: Signal transduction and targeted therapy
April 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Signal transduction and targeted therapy

DOI

EISSN

2059-3635

ISSN

2095-9907

Publication Date

April 2021

Volume

6

Issue

1

Start / End Page

168

Related Subject Headings

  • SARS-CoV-2
  • Protein Transport
  • Lysosomes
  • Humans
  • HEK293 Cells
  • Endosomes
  • COVID-19 Drug Treatment
  • COVID-19
  • Benzylisoquinolines
  • Angiotensin-Converting Enzyme 2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huang, L., Yuen, T.-T., Ye, Z., Liu, S., Zhang, G., Chu, H., & Yue, J. (2021). Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal Transduction and Targeted Therapy, 6(1), 168. https://doi.org/10.1038/s41392-021-00584-6
Huang, Lihong, Terrence Tsz-Tai Yuen, Zuodong Ye, Shuyan Liu, Guoliang Zhang, Hin Chu, and Jianbo Yue. “Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.Signal Transduction and Targeted Therapy 6, no. 1 (April 2021): 168. https://doi.org/10.1038/s41392-021-00584-6.
Huang L, Yuen TT-T, Ye Z, Liu S, Zhang G, Chu H, et al. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal transduction and targeted therapy. 2021 Apr;6(1):168.
Huang, Lihong, et al. “Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.Signal Transduction and Targeted Therapy, vol. 6, no. 1, Apr. 2021, p. 168. Epmc, doi:10.1038/s41392-021-00584-6.
Huang L, Yuen TT-T, Ye Z, Liu S, Zhang G, Chu H, Yue J. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal transduction and targeted therapy. 2021 Apr;6(1):168.

Published In

Signal transduction and targeted therapy

DOI

EISSN

2059-3635

ISSN

2095-9907

Publication Date

April 2021

Volume

6

Issue

1

Start / End Page

168

Related Subject Headings

  • SARS-CoV-2
  • Protein Transport
  • Lysosomes
  • Humans
  • HEK293 Cells
  • Endosomes
  • COVID-19 Drug Treatment
  • COVID-19
  • Benzylisoquinolines
  • Angiotensin-Converting Enzyme 2